Compare KHC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KHC | ILMN |
|---|---|---|
| Founded | 1869 | 1998 |
| Country | United States | United States |
| Employees | N/A | 8650 |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 21.8B |
| IPO Year | 2015 | 2000 |
| Metric | KHC | ILMN |
|---|---|---|
| Price | $23.89 | $144.76 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 17 |
| Target Price | $24.50 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 13.1M | 1.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.14% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 0.67 | ★ 0.87 |
| Revenue | ★ $24,942,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $0.58 | $5.58 |
| P/E Ratio | ★ $35.21 | $166.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.04 | $78.80 |
| 52 Week High | $29.19 | $155.53 |
| Indicator | KHC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 62.98 |
| Support Level | $23.55 | $116.54 |
| Resistance Level | $24.59 | $152.36 |
| Average True Range (ATR) | 0.69 | 5.32 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 86.89 | 65.04 |
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for around 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.